Image by Robert Benson | Courtesy of Bulfinch Cos.

A Canadian biotech firm will open a new U.S. headquarters in Needham at a property that’s attracted life science and tech tenants under Bulfinch Cos.’ ownership.

Vancouver-based Xenon Pharmaceuticals leased 17,000 square feet at 117 Kendrick St. The clinical-stage biotech is developing treatments for epilepsy and other neurological disorders.

Xenon Pharmaceuticals currently has local offices at 470 Atlantic Ave. in Boston and issued an initial public offering in June priced to raise $60 million.

Since acquiring the property in 2014, Bulfinch Companies repositioned the 213,000-square-foot office building for life science uses and attracted additional industry tenants including Candel Therapeutics and Verastem Oncology.

The property currently has office and lab space ranging from 17,000 to 31,000 square feet available.

Newmark represented ownership in the latest transaction. CBRE represented Xenon Pharmaceuticals.